Background: The BacterioScan 216Dx laser microbial growth monitoring system was evaluated as an option for preurine culture screening of preserved urine specimens at an acute care medical center.
Urine cultures (URNCs) are typically utilized as the standard of care to diagnose symptomatic and asymptomatic urinary tract infections (UTIs) and catheter associated UTIs (CAUTIs). 1 A UTI can be defined as acute complicated or uncomplicated cystitis and typically involves acute onset of dysuria in a person with no known functional or anatomical abnormality of the urinary tract. [2] [3] [4] [5] [6] Patients with symptomatic UTI often experience symptoms of fever, urgency, frequent dysuria, suprapubic tenderness, and potential altered mental status. [3] [4] [5] [6] A CAUTI is defined as a case of UTI that is associated with an indwelling urinary catheter. 7 Urinalysis (UA) is utilized as a screen for pyuria, which is indicative of inflammation in the genitourinary tract due to increased polymorphonuclear leukocytes. 6, 7 Importantly, an estimated 8 million medical (general outpatient, urgent care and emergency department) visits are attributable to a UTI. 2, 8 The objective of this study was to evaluate the BacterioScan 216x laser microbial growth monitor system as a pre-URNC screen for preserved urine specimens in comparison to URNC and UA, when performed per clinician orders.
While a negative UA has a high negative predictive value (NPV) for a negative URNC, a positive UA is not useful in differentiating catheterized patients with asymptomatic bacteriuria from patients with a UTI. [3] [4] [5] In some clinical settings, a positive UA screen with reflex to URNC has been utilized to reduce negative URNC setup, minimize empiric antibiotic treatment, and limit the number of false positive (FP) URNC due to CAUTI reporting guidelines. [3] [4] [5] 9 hospital-acquired infections. [9] [10] [11] [12] It is important to note that the majority of patients with a CAUTI are asymptomatic and may not have associated fever, and that UA cannot be used to rule out a UTI if the UA result is negative in a catheterized patient. 13 The considerable morbidity associated with nosocomial UTIs contributes to increased healthcare costs, as well as the potential for urosepsis. [14] [15] [16] [17] Thomas Jefferson University Hospitals (TJUH) include an academic medical center hospital, a specialty hospital, a community hospital and multiple urban ambulatory offices. Roughly, 3400 URNCs are processed monthly in the centralized microbiology laboratory. Of the URNCs performed, on average 60% to 70% are typically negative for organism growth (2015 internal data). At the time of this study, a positive UA reflex to URNC algorithm was not in performance at this institution. As such the BacterioScan system was evaluated to see if it would fit into the normal workflow of the laboratory for UTI diagnosis as a preculture screen to exclude plating of BacterioScan-negative urines. We assessed the BacterioScan system to determine it would be reliable for screening urine specimens prior to setup of the urine specimen for culture. The performance, laboratory workflow impact, and the economics of the BacterioScan system when compared to URNC as the standard of care were determined. Additionally, UA was compared to URNC to determine if UA performance as part of a potential positive UA to URNC reflex algorithm. 
Materials and Methods

BacterioScan Dilution Protocol for Preserved Urine Specimens
The BacterioScan cartridges accept either preserved or fresh urine specimens. Preserved urine specimens require a filtration and dilution protocol. All specimens received within our laboratory are preserved. Initially, the preserved urine specimens are vortexed. The sterile cuvette tray is opened under a Class 2A biosafety cabinet, and 360 µL of each specimen is aseptically pipetted (Aerosol Filter Pipet Ultrafine Tips, VWR Internationally, LLC, Radnor, PA) into the individually designated filtration microcuvette cartridge well (4 test wells per microcuvette cartridge). Then 2500 µL of Tryptic Soy Broth (Sigma-Aldrich, St. Louis, MO) is pipetted (Sterile Macro Pipet Tips, VWR Internationally, LLC, Radnor, PA) into each cuvette well to a final volume of 2860 µL per cuvette well. The lid of each cuvette well is closed, and the single cuvette barcode is scanned. Specimens are then scanned into the BacterioScan A322A instrument in the order the cuvette wells were inoculated. After incubation and analysis onboard the instrument, the cartridge containing the incubated and analyzed urine specimens are discarded per biosafety protocols.
Urinalysis System
The Iris iQ200ELITE (Beckman Coulter, Brea, CA) is utilized as the automated UA system for patient testing. Based on the UA to URNC reflex algorithm that is proposed, but not currently active, by Infection Control at TJUH, the following parameters were utilized to determine if a UA was positive and would thus reflex to URNC: when WBCs >5/hpf and leukocyte esterase ≥1; or nitrite positive with WBCs >5/hpf; or nitrite positive with leukocyte esterase ≥1; or WBCs >10/ hpf alone; or leukocyte esterase ≥2 alone. The positive UA to URNC algorithms are defined by each individual institution. 4 UA results were available only if the UA was ordered as part of the patient care order set.
Statistics
Statistics were performed on the GraphPad Prism 7.02 software (GraphPad Software, Inc, La Jolla, CA) along with corresponding 95% confidence interval (CI).
Results
A The sensitivity, specificity, positive predictive value (PPV), NPV, and accuracy of the BacterioScan system were compared to those of the traditional URNC as the gold standard in this scenario ( Table 1) . If contaminated/mixed bacterial growth occurred and BacterioScan flagged the result as "negative" for growth, the BacterioScan result was considered to be in agreement with that of the URNC. The results were considered discrepant when contaminated/mixed bacterial growth occurred, but the BacterioScan flagged the specimen "positive" for growth.
Based on Cumitech 2c: Laboratory Diagnosis of Urinary Tract
Infections, 1 culture growth was defined as potentially contaminated/mixed cultures based on the following criteria: normal flora in low numbers (<10,000 CFU/mL), or cultures containing at least 2 isolates at less than 10,000 CFU/mL each. Additionally, cultures that grew the following were counted as potential contaminants: coagulase-negative Staphylococcus (<50,000 CFU/mL); Corynebacterium species, not urealyticum (<100,000 CFU/mL); Lactobacillus species (<100,000 CFU/ mL); or any typical pathogen <10,000 CFU/mL, especially when multiple isolate types grew. Potential contaminated/ mixed cultures occur when a URNC specimen is not properly collected at the time of sample acquisition. 
Discussion
When evaluating a new diagnostic or screening assay, the laboratory must consider its analytical performance. 18 A verification and validation procedures document, Cumitech 31A, recommends that screening tests have a high sensitivity and a NPV of >95% in order to be considered acceptable for the clinical diagnostic laboratory. [18] [19] [20] Both the BacterioScan and the UA assays are screen tests, and as such an overall NPV of 93% and 89%, respectively, are lower than acceptable for confident implementation in diagnostic testing for rule-out of a negative UTI. While outpatient specimens appear to have an improved NPV of 94% for BacterioScan and 95% for UA, fewer outpatient specimens were analyzed by BacterioScan (69) and UA (51) than inpatient specimens (541 by Bacterioscan and 363 by UA). In this evaluation, the false negative (FN) results are more concerning than the FP screens. The FP urine specimens will be plated with the normal URNC workup, and potential contaminated/mixed cultures can be distinguished in the culture process. A false negative result would prevent the clinician from knowing that the patient had a "true positive" URNC. Additionally, laboratory workflow does not separate outpatient and inpatient specimens for setup or for reading culture.
Since BacterioScan is based on turbidity, it requires actively growing cells to be an effective screen. Antibiotic treatment may delay growth of the organisms. We looked at specimens tested to determine if any patients with FN urine had received antibiotics. Of the 610 specimens tested, 162 of patients had been given antibiotic/s within 7 days of urine collection. Of these 162 patients on antibiotics, 12 patients had a FN BacterioScan result. The number of FN BacterioScan specimens from patients who were on antibiotics at the time of urine collection was not significant.
While numerous organisms can cause a UTI, the following organisms are of particular concern, since they are associated with a higher rate of frequency, bacteriuria, and also urosepsis or sepsis: Escherichia coli, Klebsiella pneumoniae, Klebsiella oxytoca, and Stenotrophomonas maltophilia. BacterioScan and/or UA were FN for these isolates at sufficient enough quantities to be of concern for the reliability of these screening assays ( Table 2) . Additionally, both UA and BacterioScan were FN for yeast and Streptococcus agalactiae. Importantly, the frequency of group B Streptococcus carriage within the pregnant female population makes it problematic to incorporate a urine screening assay. False negative urine screens for Candida species can be problematic in the acute care setting with patients who have an elevated risk for disseminated disease. 4, 7, 21 The economic impact associated with BacterioScan plus plating of urine specimens that were flagged positive by BacterioScan would be substantial. BacterioScan screening would reduce the technologist time for reporting negative cultures and also the TAT of a negative URNC. BacterioScan had 175 (29%) positive with 435 (71%) negative specimens. BacterioScan was negative for 155 (25%) of the specimens that grew potential contaminated/mixed cultures. This would mean that approximately 25% of these urine specimens could avoid URNC setup if BacterioScan was applied as the pre-URNC screen. The cost avoidance (estimated to be $87,100 in URNC supplies) associated with not plating negative urine specimens is based on a 65% negativity rate for 50,000 URNCs. In addition, the test cuvettes for a daily positive and negative control per 24 hours per analyzer would cost an estimated $11,388 annually.
BacterioScan setup requires manual inoculation of each cuvette and manual loading onto the BacterioScan A322A instrument. The technologist time required to manually set up each specimen on BacterioScan would be a step back for laboratories with an automated plating system. Laboratories with an automated plating system would not likely see a benefit on the front end of the URNC process, since automation allows rapid setup of cultures with minimum technologist involvement. 22, 23 Since the cartridges are small with limited cuvette real estate, an individual urine accession label for each cuvette cannot be applied. A primary barcode for the specific cartridge is used to activate the cartridge on the analyzer, and the technologist must ensure specimens are scanned into the system in the correct order.
Studies have shown that different rapid automated systems for the diagnosis of UTIs are useful in an outpatient population, but not as beneficial for rapid diagnosis of UTIs within a medically complex group of hospitalized patients. 24, 25 Importantly, it has been shown that roughly 90% of asymptomatic elderly patients present with a FP UA. 3 Unfortunately, data are limited regarding the impact of a positive UA reflex to a URNC on both the laboratory and patient outcomes, most likely due to a lack of standardized guidelines for defining a positive UA result for a reflex algorithm. 4 The data from this study supports the above observations, that a UA and/or BacterioScan test, used as a standalone screen, may miss a number of true UTI cases. Aside from poor performance, the real benefit would be to determine if this system can be used to eliminate unnecessary antibiotics for patients through earlier culture-negative results (TAT <4 hours) and eliminate some of the workup-associated specimens contaminated during the collection process. Due to the poor performance of the assay, it would not be advisable within a high-risk acute care population to consider implementing the BacterioScan platform as a standalone prescreen for urine. This assay could have clinical utility if paired with a URNC to allow earlier reporting of probable positive and negative urine specimens within 4 hours of receipt within the laboratory; however, the additive cost of the assay may be prohibitive. LM
